دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Effect of Maternal Docosahexaenoic Acid Supplementation on Bronchopulmonary Dysplasia–Free Survival in Breastfed Preterm Infants: A Randomized Clinical Trial
Isabelle Marc, MD, PhD; Bruno Piedboeuf, MD; Thierry Lacaze-Masmonteil, MD, PhD; et al.
doi : 10.1001/jama.2020.8896
JAMA. 2020;324(2):157-167.
This randomized clinical trial compares the effects of maternal docosahexaenoic acid supplementation from childbirth through 36 weeks’ postmenstrual age vs placebo on bronchopulmonary dysplasia–free survival in breastfed infants born before 29 weeks of gestation.
Association of Angiotensin-Converting Enzyme Inhibitor or Angiotensin Receptor Blocker Use With COVID-19 Diagnosis and Mortality
Emil L. Fosbøl, MD, PhD; Jawad H. Butt, MD; Lauge Østergaard, MD; et al.
doi : 10.1001/jama.2020.11301
JAMA. 2020;324(2):168-177.
This cohort study uses Danish registry data to estimate the association between a prescription for angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) in the 6 months prior to a coronavirus disease 2019 (COVID-19) diagnosis and mortality among all patients and those with hypertension.
Association of Radial Artery Graft vs Saphenous Vein Graft With Long-term Cardiovascular Outcomes Among Patients Undergoing Coronary Artery Bypass Grafting
Mario Gaudino, MD; Umberto Benedetto, MD; Stephen Fremes, MD; et al.
doi : 10.1001/jama.2020.8228
JAMA. 2020;324(2):179-187.
This meta-analysis uses individual participant data from clinical trials to estimate associations between radial artery vs saphenous vein grafting techniques and cardiovascular outcomes at 10 years among patients undergoing coronary artery bypass grafting (CABG).
Hospital-Wide SARS-CoV-2 Antibody Screening in 3056 Staff in a Tertiary Center in Belgium
Deborah Steensels, PharmD, PhD; Els Oris, MD; Laura Coninx, MSc, PhD; et al.
doi : 10.1001/jama.2020.11160
JAMA. 2020;324(2):195-197.
This study characterizes the prevalence of antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) among hospital staff of a Belgian tertiary care center tested over 1 week in April 2020, and risk factors for seropositivity.
Changes in Hospital-Based Obstetric Services in Rural US Counties, 2014-2018
Katy B. Kozhimannil, PhD, MPA; Julia D. Interrante, MPH; Mariana K. S. Tuttle, MPH; et al.
doi : 10.1001/jama.2020.5662
JAMA. 2020;324(2):197-199.
This study describes hospital-based obstetric service losses in rural US counties between 2014 and 2018 overall and by county population and urban adjacency.
Monoclonal Antibodies for Prevention and Treatment of COVID-19
Mary Marovich, MD; John R. Mascola, MD; Myron S. Cohen, MD
doi : 10.1001/jama.2020.10245
JAMA. 2020;324(2):131-132.
This Viewpoint discusses the potential role of neutralizing monoclonal antibodies (MAbs) as a treatment for coronavirus disease 2019 (COVID-19) and as a means of prevention in high-risk populations, and it also raises possible limitations of the approach that need to be disproven or addressed for the strategy to be effective.
The Urgency and Challenge of Opening K-12 Schools in the Fall of 2020
Joshua M. Sharfstein, MD; Christopher C. Morphew, PhD
doi : 10.1001/jama.2020.10175
JAMA. 2020;324(2):133-134.
This Viewpoint proposes a policy framework for reopening of US primary, middle, and high schools (kindergarten through 12th grade) in fall 2020, including ramping up community public health responses in the summer, symptom screening of students, and privileging return-to-school decisions for younger children and others at risk for education disparities.
Medicaid and COVID-19: At the Center of Both Health and Economic Crises
Heidi L. Allen, PhD, MSW; Benjamin D. Sommers, MD, PhD
doi : 10.1001/jama.2020.10553
JAMA. 2020;324(2):135-136.
This Viewpoint discusses the financial pressures placed on US state budgets from the likely growth of Medicaid rolls during the COVID-19 pandemic, and proposes financing and policy adjustments to assist states in providing lifeline health care to low-income individuals during the crisis.
Sustaining Rural Hospitals After COVID-19: The Case for Global Budgets
Jonathan E. Fried, MD, MPP; David T. Liebers, MD, MPP, MPhil; Eric T. Roberts, PhD
doi : 10.1001/jama.2020.9744
JAMA. 2020;324(2):137-138.
This Viewpoint proposes that global budgets, or fixed payments for care of a population over a specific time, are well suited to address the financial instability wrought by the COVID-19 pandemic on rural hospitals, removing the link between volume and revenue and allowing them to adapt to community needs.
Making Decisions in a COVID-19 World
Baruch Fischhoff, PhD
doi : 10.1001/jama.2020.10178
JAMA. 2020;324(2):139-140.
This Viewpoint acknowledges the urgent need for answers to coronavirus-related public health questions such as individuals’ risk for coronavirus disease 2019 (COVID-19) exposure and disease if workplaces, schools, and businesses reopen, and emphasizes the need to translate cross-disciplinary science into usable form for policy decision makers, risk analysts, and the public.
Airborne Spread of SARS-CoV-2 and a Potential Role for Air Disinfection
Edward A. Nardell, MD; Ruvandhi R. Nathavitharana, MD, MPH
doi : 10.1001/jama.2020.7603
JAMA. 2020;324(2):141-142.
In the context of potential aerosol spread of SARS-CoV-2 infection, this Viewpoint argues for use of upper-room germicidal UV (GUV) fixtures as a means to disinfect circulating air and prevent spread of COVID-19 and other infections in health care settings.
Shortcomings in the US Pharmaceutical Supply Chain: Potential Risks Associated With International Manufacturing and Trade-Related Tariffs
Richard L. Oehler, MD; Sandra G. Gompf, MD
doi : 10.1001/jama.2020.1634
JAMA. 2020;324(2):143-144.
This Viewpoint discusses vulnerabilities in the US drug supply chain given a shift in manufacturing of pharmaceutical ingredients to other countries and calls for a system to identify high-value medications, forecast supplies and shortages, and incentivize domestic production.
Regulating Medicines in a Globalized World With Increased Recognition and Reliance Among Regulators: A National Academies Report
Lawrence O. Gostin, JD; Alastair J. Wood, MD; Patricia A. Cuff, MS, MPH
doi : 10.1001/jama.2019.21793
JAMA. 2020;324(2):145-146.
This Viewpoint summarizes recommendations from a 2020 National Academies of Sciences, Engineering, and Medicine (NASEM) committee report on ways to improve regulatory oversight of drugs in an era of global pharmaceutical research and development.
Sustainability, Business, and Health
George Serafeim, DBA; Amanda M. Rischbieth, PhD; Howard K. Koh, MD, MPH
doi : 10.1001/jama.2020.8714
JAMA. 2020;324(2):147-148.
This Viewpoint discusses examples of how many private sector businesses have aligned their core missions with civil and human rights and sustainability reforms, and emphasizes the importance of engaging the sector in achieving public health goals and accelerating worldwide recovery from the COVID-19 pandemic.
“Are You Wearing Your White Coat?”: Telemedicine in the Time of Pandemic
Marcin Chwistek, MD
doi : 10.1001/jama.2020.10619
JAMA. 2020;324(2):149-150.
In this narrative medicine essay, a palliative medicine physician reflects on what is gained and lost in the turn toward telemedicine during the COVID-19 pandemic from a cornerstone belief that the in-person encounter is an anchoring condition for the patient-physician relationship.
Thinking of Risk in the Era of COVID-19
Howard Bauchner, MD; Phil Fontanarosa, MD, MBA
doi : 10.1001/jama.2020.10242
JAMA. 2020;324(2):151-153.
-----
Coronary Revascularization Strategies: Making Sense of Sparse, Limited-Quality Data
Steven E. Nissen, MD; Faisal G. Bakaeen, MD
doi : 10.1001/jama.2020.8548
JAMA. 2020;324(2):154-156.
-----
Use of Run-in Periods in Randomized Trials
Xiqian Huo, MD, PhD; Jane Armitage, MBBS
doi : 10.1001/jama.2020.6463
JAMA. 2020;324(2):188-189.
This JAMA Guide to Statistics and Methods reviews the use of prerandomization run-in periods to improve treatment adherence and reduce loss to follow-up, and explains how they should be interpreted.
Caring for Women Who Are Planning a Pregnancy, Pregnant, or Postpartum During the COVID-19 Pandemic
Sonja A. Rasmussen, MD, MS; Denise J. Jamieson, MD, MPH
doi : 10.1001/jama.2020.8883
JAMA. 2020;324(2):190-191.
This JAMA Insights Clinical Update discusses what is known about the epidemiology and effects of SARS-CoV-2 infection in pregnancy, and summarizes Centers for Disease Control and Prevention (CDC) and professional organization (AAP and ACOG) recommendations for care of pregnant women with COVID-19.
Peanut Allergen Powder (Palforzia)
-
doi : 10.1001/jama.2020.3599
JAMA. 2020;324(2):192-193.
This Medical Letter review summarizes the dosing, administration, cost, and adverse effects use of peanut allergen powder-dnfp (Palforzia), an oral immunotherapy indicated to mitigate allergic reactions, including anaphylaxis, caused by accidental peanut exposure in patients with a confirmed peanut allergy.
Renin-Angiotensin-Aldosterone Inhibitors and Susceptibility to and Severity of COVID-19
Gregory Curfman, MD
doi : 10.1001/jama.2020.11401
JAMA. 2020;324(2):177-178.
-----
“Abandoned” Nursing Homes Continue to Face Critical Supply and Staff Shortages as COVID-19 Toll Has Mounted
Jennifer Abbasi
doi : 10.1001/jama.2020.10419
JAMA. 2020;324(2):123-125.
This Medical News article discusses nursing homes’ ongoing challenges during the novel coronavirus pandemic.
Resilience in Health Care Financing
Karen Murphy, PhD, RN; Ryan Koski-Vacirca, BS; Joshua Sharfstein, MD
doi : 10.1001/jama.2020.10417
JAMA. 2020;324(2):126-127.
-----
Norovirus Spread Among Hundreds of 2018 California Fire Evacuees
Bridget M. Kuehn, MSJ
doi : 10.1001/jama.2020.11551
JAMA. 2020;324(2):129.
-----
Connecting Refugees With Follow-up Care for Hepatitis B
Bridget M. Kuehn, MSJ
doi : 10.1001/jama.2020.10632
JAMA. 2020;324(2):129.
-----
Autologous Brain Cell Transplant for Parkinson Disease
Jennifer Abbasi
doi : 10.1001/jama.2020.11581
JAMA. 2020;324(2):128.
-----
Researchers Home in on COVID-19 Severity Biomarkers
Jennifer Abbasi
doi : 10.1001/jama.2020.11397
JAMA. 2020;324(2):128.
-----
COVID-19 Antibody Trials Have Begun
Jennifer Abbasi
doi : 10.1001/jama.2020.11582
JAMA. 2020;324(2):128.
-----
Morning Report—: To a Poet Who Thinks He Understands
Brenda J. Butka, MD
doi : 10.1001/jama.2020.0121
JAMA. 2020;324(2):202.
-----
What Is Anosmia?
Pauline P. Huynh, BA; Lisa E. Ishii, MD, MHS; Masaru Ishii, MD, PhD
doi : 10.1001/jama.2020.10966
JAMA. 2020;324(2):206.
This JAMA Patient Page describes the causes, diagnosis, and treatment options for anosmia and olfactory dysfunction.
Hydroxyethyl Starch vs Saline for Volume Expansion After Abdominal Surgery
Edward J. Mascha, PhD
doi : 10.1001/jama.2020.6980
JAMA. 2020;324(2):199.
-----
Hydroxyethyl Starch vs Saline for Volume Expansion After Abdominal Surgery
Gregor Markow, MD, MSc
doi : 10.1001/jama.2020.6971
JAMA. 2020;324(2):199.
-----
Hydroxyethyl Starch vs Saline for Volume Expansion After Abdominal Surgery
Fu-Shan Xue, MD; Shao-Hua Liu, MD; Liu-Jia-Zi Shao, MD
doi : 10.1001/jama.2020.6977
JAMA. 2020;324(2):199-200.
-----
Hydroxyethyl Starch vs Saline for Volume Expansion After Abdominal Surgery
Daniel De Backer, MD, PhD; Gregoire Michiels, MD
doi : 10.1001/jama.2020.6974
JAMA. 2020;324(2):200.
-----
Hydroxyethyl Starch vs Saline for Volume Expansion After Abdominal Surgery—Reply
Emmanuel Futier, MD, PhD; Bruno Pereira, PhD; Samir Jaber, MD, PhD
doi : 10.1001/jama.2020.6983
JAMA. 2020;324(2):200-201.
-----
